Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
The Lancet. Respiratory medicine（2023）
摘要
For the Chinese translation of the abstract see Supplementary Materials section.
更多查看译文
关键词
lung cancer,sintilimab,egfr-mutated,non-squamous,non-small-cell,tyrosine-kinase,double-blind,placebo-controlled
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要